Global Cancer Vaccine Partnering Terms and Agreements Report and Directory 2022: Contract Documents for Over 350 Deals – Trends, Key Players, Top Deal Values, and Deal Financials 2010-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Cancer Vaccine Partnering Terms and Agreements 2010-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2022 report provides comprehensive access to available deals and contract documents for over 350 Cancer Vaccine deals.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 350 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announced by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Global Cancer Vaccine Partnering Terms and Agreements 2010-2022 provides the reader with the following key benefits:

• In-depth understanding of Cancer Vaccine deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
• Identify most active Cancer Vaccine dealmakers since 2010
• Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sale sand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

In Global Cancer Vaccine Partnering Terms and Agreements 2010-2022, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

 

Key Topics Covered:

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Cancer Vaccine dealmaking

2.1. Introduction

2.2. Cancer Vaccine partnering over the years

2.3. Most active Cancer Vaccine dealmakers

2.4. Cancer Vaccine partnering by deal type

2.5. Cancer Vaccine partnering by therapy area

2.6. Deal terms for Cancer Vaccine partnering

2.6.1 Cancer Vaccine partnering headline values

2.6.2 Cancer Vaccine deal upfront payments

2.6.3 Cancer Vaccine deal milestone payments

2.6.4 Cancer Vaccine royalty rates

 

Chapter 3 – Leading Cancer Vaccine deals

3.1. Introduction

3.2. Top Cancer Vaccine deals by value

 

Chapter 4 – Most active Cancer Vaccine dealmakers

4.1. Introduction

4.2. Most active Cancer Vaccine dealmakers

4.3. Most active Cancer Vaccine partnering company profiles

 

Chapter 5 – Cancer Vaccine contracts dealmaking directory

5.1. Introduction

5.2. Cancer Vaccine contracts dealmaking directory

 

Chapter 6 – Cancer Vaccine dealmaking by technology type

 

Appendices

Appendix 1 – Cancer Vaccine deals by company A-Z

Appendix 2 – Cancer Vaccine deals by stage of development

• Discovery
• Preclinical
• Phase I
• Phase II
• Phase III
• Regulatory
• Marketed
• Formulation

Appendix 3 – Cancer Vaccine deals by deal type

• Asset purchase
• Assignment
• Bigpharma outlicensing
• Co-development
• Collaborative R&D
• Co-market
• Co-promotion
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Litigation
• Manufacturing
• Marketing
• Material transfer
• Option
• Promotion
• Research
• Settlement
• Spin out
• Sub-license
• Supply
• Technology transfer
• Termination
• Warranty

Appendix 4 – Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions

Appendix 6 – Further reading on dealmaking

Companies Mentioned

• 2A
• 3D Medicines
• A*STAR Bioprocessing Technology Institute
• Aura Biosciences
• Averion
• AV Therapeutics
• Beth Israel Deaconess Medical Center
• BGI
• CureLab Oncology
• CureVac
• Cyplasin Biomedical
• CYTLIMIC
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Dalton Pharma Services
• Exiqon
• ExpreS2ion Biotechnologies
• Federal Ministry of Education and Research (BMBF)
• Flaskworks
• Georgia Health Sciences University
• GeoVax
• German Cancer Research Center
• Hookipa Pharma
• Human Vaccines Project
• iBio
• Icahn School of Medicine at Mount Sinai
• Ichor Medical Systems
• Leukaemia & Lymphoma Research
• LG Life Sciences
• Ligand Pharmaceuticals
• Massachusetts Life Sciences Center
• Mayo Clinic
• National Research Council Canada
• National Surgical Adjuvant Breast and Bowel Project
• OncoQR
• OncoSec Medical
• Oncotherapy Science
• PsiOxus Therapeutics
• Pulmotec
• PX Biosolutions
• Qiagen
• Radboud University Nijmegen Medical Centre
• Selecta Biosciences
• Selexis
• Sellas Clinicals Holding
• Seres Therapeutics
• Telormedix
• Teva Pharmaceutical Industries
• VGX International
• Vinnova
• ViroMed
• Vivalis
• VLP Therapeutics
• VLST Corporation
• Y-mAbs Therapeutics
• Yale University
• Yamaguchi University

For more information about this report visit https://www.researchandmarkets.com/r/smuwbv.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900